CN Patent

CN103804356A — 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形

Assigned to Novartis AG · Expires 2014-05-21 · 12y expired

What this patent protects

本发明涉及4-甲基-N-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形或多晶形，以及制备它们的方法、包含它们的药物组合物以及使用它们治疗的方法。

USPTO Abstract

本发明涉及4-甲基-N-[3-(4-甲基-咪唑-1-基)-5-三氟甲基-苯基]-3-(4-吡啶-3-基-嘧啶-2-基氨基)-苯甲酰胺的晶形或多晶形，以及制备它们的方法、包含它们的药物组合物以及使用它们治疗的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN103804356A
Jurisdiction
CN
Classification
—
Expires
2014-05-21
Drug substance claim
No
Drug product claim
No
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.